A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dual agonism of glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor may be more effective than GLP-1 receptor agonism alone for treating metabolic dysfunction-associated steatohepatitis (MASH). The efficacy and safety of survodutide (a dual agonist of glucagon receptor and GLP-1 receptor) in persons with MASH and liver fibrosis are unclear. METHODS: In this 48-week, phase 2 trial, we randomly assigned adults with biopsy-confirmed MASH and fibrosis stage F1 through F3 in a 1:1:1:1 ratio to receive once-weekly subcutaneous injections of survodutide at a dose of 2.4, 4.8, or 6.0 mg or placebo. The trial had two phases: a 24-week rapid-dose-escalation phase, followed by a 24-week maintenance phase. The primary end point was histologic improvement (reduction) in MASH with no worsening of fibrosis. Secondary end points included a decrease in liver fat content by at least 30% and biopsy-assessed improvement (reduction) in fibrosis by at least one stage. RESULTS: A total of 293 randomly assigned participants received at least one dose of survodutide or placebo. Improvement in MASH with no worsening of fibrosis occurred in 47% of the participants in the survodutide 2.4-mg group, 62% of those in the 4.8-mg group, and 43% of those in the 6.0-mg group, as compared with 14% of those in the placebo group (P<0.001 for the quadratic dose-response curve as best-fitting model). A decrease in liver fat content by at least 30% occurred in 63% of the participants in the survodutide 2.4-mg group, 67% of those in the 4.8-mg group, 57% of those in the 6.0-mg group, and 14% of those in the placebo group; improvement in fibrosis by at least one stage occurred in 34%, 36%, 34%, and 22%, respectively. Adverse events that were more frequent with survodutide than with placebo included nausea (66% vs. 23%), diarrhea (49% vs. 23%), and vomiting (41% vs. 4%); serious adverse events occurred in 8% with survodutide and 7% with placebo. CONCLUSIONS: Survodutide was superior to placebo with respect to improvement in MASH without worsening of fibrosis, warranting further investigation in phase 3 trials. (Funded by Boehringer Ingelheim; 1404-0043 ClinicalTrials.gov number, NCT04771273; EudraCT number, 2020-002723-11.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationA multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Self-citationA phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citationChanging epidemiology, global trends and implications for outcomes of NAFLD
Wong, V. W.-S., Ekstedt, M., Wong, G. L.-H., & Hagström, H. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.036 · Cited by 765
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
Loomba, R., Sanyal, A. J., Kowdley, K. V., Bhatt, D. L., Alkhouri, N., Frias, J. P., Bedossa, P., Harrison, S. A., Lazas, D., Barish, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304286 · Cited by 522
Self-citationGlucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
Pocai, A., Carrington, P. E., Adams, J. R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M. E., Jiang, G., et al. (2009) · Diabetes · doi:10.2337/db09-0278 · Cited by 409
Nahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P. (2021) · Diabetes Care · doi:10.2337/dc20-2151 · Cited by 323
Cited by
Items 201–300 of 537
Ren, T., Eslam, M., & Fan, J. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0558 · Cited by 11
Gonzalez, F. J., & Xia, Y. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.10.046 · Cited by 8
Park, C., Kim, Y., Raygani, S., & Grunvald, E. L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1630199 · Cited by 7
Banerjee, M., Pal, R., & Pal, S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70187 · Cited by 9
“5,7 We did not include trials on liraglutide 20 or pioglitazone 21 because these trials did not explicitly report the specific composite outcome of “ fibrosis improvement of at least one stage without worsening of steatohepatitis ” which was the primary outcome of our analysis.”
Austrian multisociety consensus on metabolic dysfunction-associated steatotic liver disease
Mandorfer, M., Semmler, G., Aigner, E. S., Bräuer, A., Brix, J. M., Clodi, M., Datz, C., Effenberger, M., Felsenreich, D. M., Ludvik, B. H., et al. (2025) · Wiener klinische Wochenschrift · doi:10.1007/s00508-025-02617-4 · Cited by 8
Advances in Incretin‐Based Therapies for MAFLD: Mechanisms and Clinical Evidence
Dong, W., Zhang, H., Mu, S., Shi, S., Zhang, J., & Xu, K. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70131 · Cited by 7
Liver disease in people living with HIV infection: a changing landscape
Lee, F., & Bansal, M. B. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01149-6 · Cited by 8
“…placebo), and GLP1–glucagon receptor agonists, such as survodutide (NCT04771273; total of 293 patients equally distributed to 2.4 mg, 4.8 mg, 6.0 mg or placebo), have both shown positive phase II results for MASH resolution with trends to fibrosis improvement, and we await phase III data 138,139 .”
InfluentialTincopa, M. A., Speliotes, E. K., Valenti, L. V. C., & Loomba, R. S. (2026) · Annual Review of Medicine · doi:10.1146/annurev-med-050324-124753 · Cited by 8
Tsakiridis, E. E., & Steinberg, G. R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70624 · Cited by 10
Li, F., Li, H., Juramt, D., Kou, K., Tacke, F., & Chen, L. (2026) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2026-002343 · Cited by 11
Goldney, J., & Davies, M. J. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00977-2 · Cited by 7
Kaya, E., Syn, W., & Manka, P. P. (2025) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001083 · Cited by 7
Elangovan, H., Gunton, J. E., Zheng, M., Fan, J.-G., Goh, G. B., Grønbæk, H., & George, J. (2025) · Hepatology International · doi:10.1007/s12072-025-10795-6 · Cited by 7
“…(a dual GLP1/GIP agonist) and Survodutide (a dual GLP1/ Glucagon receptor agonist) meeting their primary end-points of remitting steatohepatitis without worsening of fibrosis and improvement in fibrosis stage of ≥ 1 grade without worsening of steatohepatitis when compared with placebo [53, 54].”
Kim, M.-K., & Kim, H. S. (2024) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2024.228 · Cited by 10
Olveira, A., Crespo, J., Ibáñez, L., Gallego‐Durán, R., Calleja, J. L., Aller, R., Sòria, A., Gómez‐Camarero, J., Martín‐Mateos, R., Benlloch, S., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.08.023 · Cited by 10
Boutari, C., Hill, M. A., & Mantzoros, C. S. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156397 · Cited by 7
Wharton, S., le Roux, C. W., Bozkurt, B., Platz, E., Bleckert, G., Hussain, S. A., Brueckmann, M., Startseva, E., Kloer, I. M., & Kaplan, L. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70263 · Cited by 7
“These doses were selected based on Phase 2 trials in people with obesity, T2D and/or metabolic dysfunction-associated steatohepatitis (MASH) that together encompassed each of these doses, 16,17,20 as well as evidence from Phase 1, 21 animal and modelling studies.”
Self-citationEmerging Therapies in Metabolic Health: A Comprehensive Review of GLP‐1, GIP, and Glucagon Agonists
Khan, M. S., Bhutani, U., Venugopal, H., Saini, A. K., Naidu, V. R., & Kollipara, S. (2026) · Journal of Peptide Science · doi:10.1002/psc.70083 · Cited by 7
“Survodutide (NCT04771273) [81] demonstrated significant histologic benefits and a favorable safety profile, and combination regimens such as semaglutide with cilofexor and firsocostat (NCT03987074) [82] offered additive benefits over monotherapy.”
Brouwer, W. P., Vonghia, L., Thiele, M. S., Schattenberg, J. M., Anastasiou, F., Beckmann, S., Bugianesi, E., Castéra, L., Caussy, C., Cordie, A., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101798 · Cited by 12
“144–146 Specific considerations in individuals with cirrhosis are discussed in detail in the section on surgery in MASLD-related cACLD.”
Self-citationMonami, M., Belluzzi, A., Buscemi, S., Busetto, L., Cohen, R., Luca, M. D., Galli, A., Mannucci, E., Petry, T. B. Z., Ragghianti, B., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70617 · Cited by 10
“However, in the first trial providing data on MASH resolution and fibrosis [28], survodutide did not appear to produce benefits greater than those expected on the basis of the observed weight loss.”
EASL position paper on preclinical models of steatotic liver disease
Gallage, S., Castro, R. E., Estall, J. L., Tabas, I. A., Anstee, Q. M., TINIAKOS, D. G., Szabó, G., Yu, J., Desdouets, C., Tacke, F., et al. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.04.029 · Cited by 8
Self-citationMASLD and the cardiovascular-kidney-liver-metabolic syndrome
Angelidi, A. M., Boutari, C., Kokkorakis, M., Stefanakis, K., Mikhailidis, D. P., Jacob, G., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag023 · Cited by 7
Misceo, D., Mocciaro, G., D’Amore, S., & Vacca, M. (2024) · Nutrition & Metabolism · doi:10.1186/s12986-024-00871-3 · Cited by 7
“Dual GLP-1-GIP (e.g., tirzepatide [255]), dual GLP-1-glucagon (e.g., sur-vodutide, efinopegdutide, BI456906 [256, 257]) or triple GLP1-GIP-glucagon (e.g., retatrutide [258]) agonists are currently being tested (Phase II/III trials) in patients with Obesity, T2DM and/or MASLD [4].”
Koullias, E., Papavdi, M., Koskinas, J. S., Deutsch, M. J., & Thanopoulou, A. C. (2025) · Cureus · doi:10.7759/cureus.76716 · Cited by 13
de Souza, M. H. G., Amaral, M. J. M., Lima, L. C. V., & Villela‐Nogueira, C. A. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18498 · Cited by 6
Role of Alcohol in Steatotic Liver Disease: Impact on Patients with Cardiometabolic Risk Factors
Capinha, F., Carvalhana, S. C., & Cortez‐Pinto, H. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-08912-4 · Cited by 7
Srivastava, G., Campbell, S. L., Hill, C. R., Stanley, T. L., Lawson, E. A., Apovian, C. M., Almandoz, J. P., Leggio, L., Lakdawalla, D. N., Dar, M., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.06.015 · Cited by 5
Xia, H., Min, Y., Wang, Y., Gao, S., Wang, H., Yan, F., Liu, R., Wang, J., Gu, X., & Bo, T. (2025) · Radiology · doi:10.1148/radiol.243780 · Cited by 9
Kumar, A. (2025) · Journal of the Association of Physicians of India · doi:10.59556/japi.73.1058 · Cited by 7
Li, D., & Zhang, X. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000846 · Cited by 10
“[178,179] FGF21 is an endocrine hormone that protects hepatocytes against stress conditions through various pathways.”
Llach, J., Sòria, A., Graupera, I., & Cardenas, A. (2026) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2026.2632873 · Cited by 5
Hu, Z., Tian, D., Yang, Z., Zhang, J., Zhang, L., Xu, Y., & Lu, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1754721 · Cited by 7
“As research progresses, these dual agonists offer better therapeutic hope for patients with metabolic disorders and NASH (Sanyal et al., 2024).”
Albor, C., Anyiam, O., Boyle, L., Makaronidis, J., Tan, R. J. L., Iftikhar, S., Burzić, A., Lajeunesse‐Trempe, F., Stanley, M., Bhatti, A. I., et al. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00707-6 · Cited by 5
Liu, M., Ma, Y., Cheang, W. S., Su, Z., & Xu, S. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.04.011 · Cited by 11
Ho, M. J., Liew, C. F., Tan, N. A. M. R., Morita, A., & Oon, H. H. B. (2026) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2026.2665732 · Cited by 8
CVOT Summit Report 2025: advances along the cardiovascular–kidney–metabolic disease continuum
Schnell, O., Agarwal, A., Azizi, M., Ballwieser, D. A., Barnard-Kelly, K. D., Battelino, T., Blüher, M., Bugianesi, E., Cebrián, A., Ceriello, A., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03140-0 · Cited by 6
“Further promising results are available from phase 2 trials: the dual glucagon/GLP-1 RA survodutide reduced liver fat and improved MASH and fibrosis [123], while tirzepatide was superior to placebo for MASH resolution and fibrosis improvement in the SYNERGY-NASH trial [124].”
Self-citationBae, J. H., & Cho, Y. M. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14336 · Cited by 5
Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction
Kaya, E., Yilmaz, Y., & Alkhouri, N. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2441865 · Cited by 8
“A recently published phase 2 trial has provided additional evidence supporting the treatment’s efficacy in the context of MASH [27].”
InfluentialSelf-citationLiu, Y., Zhao, X., Wang, X., & Zhou, Q. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1534628 · Cited by 6
Incretin-based Agents and Metabolic Dysfunction-associated Steatotic Liver Disease
Muzurović, E. M., Haluzík, M., Horváth, L., Vlacho, B., & Mauricio, D. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128378484250619080753 · Cited by 5
Luong, T. V., Tran, H., Thi, B. N. C., Vu, H. M., Le, T., Le, T., Thi, H. N., Nguyen, H. M., Doan, T. C., Ho, A. B., et al. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i7.107751 · Cited by 5
Wang, Y., & Wan, S. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117423 · Cited by 7
Sebastiani, G., Raggi, P., & Guaraldi, G. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.06.075 · Cited by 8
Dinerman, S., & Shu, Y. (2025) · International Journal of Translational Medicine · doi:10.3390/ijtm5010007 · Cited by 6
“…2 trial of MASH patients (n = 293), 2.4 mg survodutide treatment once per week proved to significantly improve MASH without worsening fibrosis (47% of patients with treatment vs. 14% with placebo; p < 0.001), providing the rationale for continued investigation in a Phase 3 clinical trial [47].”
InfluentialDutta, D., Kamrul-Hasan, A. B. M., Joshi, A. S., Dhall, A., Nagendra, L., & Sharma, M. (2025) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_366_24 · Cited by 4
“[5] also demonstrated clinical benefits concerning fibrosis improvement (34% of the participants in the survodutide 6.0 mg group vs. 22% of those in the placebo group) in MASH/MASLD.”
InfluentialSafety Choice Drivers of the Coming Treatment Options for Non‐Cirrhotic Metabolic Steatohepatitis
Mangia, A., & Valenti, L. V. C. (2025) · Liver International · doi:10.1111/liv.70271 · Cited by 4
“The most frequently AEs events were GI in nature (Table 3) [65, 66].”
InfluentialNew Names, New Drugs, Better Outcomes in Steatotic Liver Disease
Peverelle, M., Mbelle, M., & Joshi, D. (2025) · British Journal of Hospital Medicine · doi:10.12968/hmed.2024.0655 · Cited by 4
Treatment Landscape of Metabolic-Dysfunction-Associated Steatotic Liver Disease
Patel, P. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14176060 · Cited by 7
“Additionally, greater reductions in other metabolic risk factors such as HDL, LDL, TGL levels, and body weight were noted in the efinopegdutide group compared with semaglutide [19].”
InfluentialBharaj, I. S., Purewal, K., Munaim, J., Brar, A. S., Kacheria, A., Simister, A., Thirupathy, U., Gupta, P., Kahlon, J., Thwe, E. E., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13092192 · Cited by 7
A Pathophysiology‐Informed, Negentropy‐Oriented Strategy for Nanomedicine in MASLD
Mao, R., Yu, M., Guo, X., Tian, X.-Q., Zhao, M., Yu, Q., Ren, G., Pan, M., Bai, R., Liu, L., et al. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202504298 · Cited by 6
Elangovan, H., Loomba, R. S., Muthiah, M. D., Schattenberg, J. M., Zheng, M., Noureddin, M., Mantzoros, C. S., & George, J. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0857 · Cited by 5
Self-citationGlucagon-Like Peptide 1 Receptor Agonists and Cardiovascular Disease
Ibe, T., & Borlaug, B. A. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-011141 · Cited by 4
Diagnosis and management of metabolic dysfunction associated steatotic liver disease
Musso, G., Lassen, A., Banda, L., Maher, J. J., & Gambino, R. (2025) · BMJ · doi:10.1136/bmj-2025-084950 · Cited by 6
Hu, W., Gu, M., Li, H., Li, H., Kan, J., Zhang, L., Ding, Q., & Zhu, Y. Z. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100125 · Cited by 5
Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis
Abreu, E. S., Noureddin, M., Takahashi, H., Schattenberg, J. M., & Abdelmalek, M. F. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.01.004 · Cited by 4
Self-citationManagement of MASLD/MASH: challenges, innovations, and the future of patient-centered care in Japan
Seko, Y., & Yamaguchi, K. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02401-9 · Cited by 4
“Clinical trials of GLP-1RA, such as semaglutide, tirzepatide, efinopegdutide, and survodutide, demonstrated safety and efficacy in improving liver steatosis and resolving MASH [112–115].”
Beyond weight loss: multisystem benefits of obesity medications
Savas, M., Kuckuck, S., Boon, M. R., & van Rossum, E. F. C. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00100-2 · Cited by 5
Newer and novel antidiabetic drug classes across the cardiovascular–kidney–metabolic continuum
Stefanakis, K., Karakasis, P., Vasdeki, D., Popovic, D. S., Patoulias, D., Rizzo, M., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag022 · Cited by 6
Huang, R., Zhang, C., Mo, X., & Rao, H. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003417 · Cited by 5
Two Trials of Therapeutics for MASH with Liver Fibrosis
Mei, Z., Pu, J., & Shao, Z. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2411003 · Cited by 4
Jayabalan, D., Dhakal, S., Chandra, J., Fasser, D. A., Jeffrey, G. P., Garas, G., Vilar-Gomez, E., Calzadilla-Bertot, L., & Adams, L. A. (2026) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003918 · Cited by 3
Mouse Models for the Study of Liver Fibrosis Regression In Vivo and Ex Vivo
Schönke, M., & Rensen, P. C. N. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00212 · Cited by 13
“…resmetirom, tirzepatide, and survodutide have all been shown to lower the fibrosis score in human MASH, seemingly without directly affecting HSCs. 9,10,12 This suggests that the reduction of intrahepatic lipids and inflammation may be sufficient for the regression of liver fibrosis, underscoring…”
7. Management of metabolic dysfunction-associated steatotic liver disease (MASLD) in type 2 diabetes
Colagiuri, S., & Ceriello, A. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112151 · Cited by 3
Multifaceted Human Antigen R (HuR): A Key Player in Liver Metabolism and MASLD
Eppler, N., Jones, E., Ahamed, F., & Zhang, Y. (2025) · Livers · doi:10.3390/livers5030033 · Cited by 5
“…(GLP-1) receptor agonists (e.g., liraglutide, semaglutide), GIP/GLP-1 dual receptor agonists (e.g., tirzepatide), glucagon/GLP-1 dual receptor agonists (e.g., pemvidutide, survodutide), and glucagon/GIP/GLP-1 triple receptor agonists (e.g., efocipegtrutide) for the treatment of MASH [14–18].”
Larsen, A. T., Melander, S. A., Mohamed, K. E., Petersen, E. A., Benmarce, M., Karsdal, M. A., & Henriksen, K. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118388 · Cited by 3
Arredouani, A. (2025) · Diabetologia · doi:10.1007/s00125-025-06527-y · Cited by 3
Kaya, E., Yilmaz, Y., & Alkhouri, N. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2566258 · Cited by 6
“Nevertheless, the findings justified progression to a phase 3 clinical trial [23].”
Self-citationSemaglutide for the treatment of MASH: reaching into the ESSENCE of cardio-metabolic health?
Mademlis, C., Patoulias, D., Koufakis, T., Teperikidis, E., Γιουλεμέ, Ό., & Doumas, M. N. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2573785 · Cited by 3
“A recent 48-week, phase 2 randomized controlled trial investigated survodutide – a dual GLP-1 and glucagon receptor agonist (GIP) – in patients with MASH and fibrosis stages F1–F3 [11].”
Yoon, E. L., Cho, J.-Y., Park, H., Kim, M., Park, J.-H., Kim, H., & Jun, D. W. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0796 · Cited by 10
Stefanakis, K., Mingrone, G., George, J., & Mantzoros, C. S. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.10.029 · Cited by 5
Wang, Y., & Peng, J. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108054 · Cited by 3
Feng, J. N., Chen, Y., & Jin, T. (2025) · Metabolism and Diseases · doi:10.1016/j.metdis.2025.100001 · Cited by 3
Long, F., Challa, T. D., Efthymiou, V., Klug, M., Klein, T., Neubauer, H., Wolfrum, C., & Horváth, C. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70359 · Cited by 3
“6,8 While semaglutide did not reduce liver TAG load, we could recapitulate enhanced TAG clearance in WT mice at both doses of BI-456908, which were ineffective in LKO mice (Figure 2G).”
Zhu, B. J. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1753393 · Cited by 3
Metabolic polygenic risk scores for prediction of obesity, type 2 diabetes, and related morbidities
Kim, M. S., Chen, Q., Sui, Y., Yang, X., Wang, S., Weng, L.-C. C., Cho, S. M. J., Koyama, S., Zhu, X., Yu, K., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.02.009 · Cited by 7
Facciorusso, A., Giannini, E. G., Tacelli, M., Zanetto, A., Spada, C., Boskoski, I., Furnari, M., Pennisi, G., Capurso, G., Vitello, A., et al. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.02.018 · Cited by 3
Cobbold, J., Miller, H., Hallsworth, K., Manousou, P., Marjot, T., Allison, M. E., Anstee, Q. M., Armstrong, M., Avery, L., Azzu, V., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00077-4 · Cited by 6
Self-citationVettor, R., Petroni, M. L., Dotan, I., Lalazar, G., Haluzík, M., Spearman, C. W., Dave, J. A., Abaalkhail, F. A., Abusnana, S., Alshehri, A. A., et al. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10027-8 · Cited by 6
Tang, M., Ma, Y., & Wang, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1829315 · Cited by 3
Capuccio, S., Cocuzza, C., Marco, G. D., Scamporrino, A., Piro, S., & Russello, M. (2026) · Nutrients · doi:10.3390/nu18142316 · Cited by 6
“Survodutide, a dual glucagon/GLP-1 receptor agonist, has also demonstrated significant efficacy in the phase 2 trial, achieving histological improvement in MASH and fibrosis, with additional benefits on hepatic fat reduction and body weight [170].”
Pharmacological treatment of MASH
Stefan, N., & Targher, G. (2026) · Diabetologia · doi:10.1007/s00125-026-06796-1 · Cited by 6
“Survodutide significantly reduced body weight and plasma lipid and HbA 1c levels compared with placebo [45].”
Hamilton, A., Thisted, L., Ougaard, M., Hahn, M., Andersen, K., Perens, J., Augustin, R., Bajrami, B., Rist, W., Christensen, M., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71387 · Cited by 3
Lopes, T., Hope, D. C. D., Pittol, J. M. R., Curtis, A., Shrewsbury, J. V., Davies, I., Zhou, Z., Sardini, A., MINNION, J. S., Dormann, D., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102024 · Cited by 3
Kanbay, M., Çöpür, S., Güldan, M., Özbek, L., Mallamaci, F., & Zoccali, C. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14330 · Cited by 4
Awad, A. A., Abouelmagd, A. A., Mohammed, F., Elettreby, A. M., Marey, M. M., Aldemerdash, M. A., Soliman, S. M., Belal, M. M., & Abosheaishaa, H. M. (2025) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2025.2480512 · Cited by 4
“20 Our meta-analysis shows that survodutide has promising results in managing obesity.”
Evolving Role of GLP-1 Therapies in Liver Disease
Lindsay, M., Arndt, G., Wieland, A. C., & Jensen, T. (2025) · Current Gastroenterology Reports · doi:10.1007/s11894-025-00988-2 · Cited by 3
“…1–3 Fibrosis compared to placebo showed superior ability in the resolution of MASH without worsening of fibrosis; 47% of the participants in the survodutide 2.4-mg group, 62% of those in the 4.8-mg group, and 43% of those in the 6.0-mg group, vs 14% of those in the placebo group (P < 0.001) [69].”
InfluentialMetabolic dysfunction-associated steatotic liver disease
Chen, C., & Liao, D.-M. (2024) · 童綜合醫學雜誌 · doi:10.4103/etmj.etmj-d-24-00019 · Cited by 3
Leite, A. R., Dias, J., Godinho, T., Correia-Chaves, J., Borges‐Canha, M., Lourenço, I. M., Leite-Moreira, A. F., & Neves, J. S. (2024) · Endocrinology Insights · doi:10.1159/000541442 · Cited by 5
Al-rubaye, S., Ferrero, T. G., Rodriguez-Perez, A. I., Camacho-Meño, L., Labandeira-García, J. L., Álvarez, E., García‐Seara, J., Bravo, S. B., González‐Juanatey, J. R., Rodríguez‐Mañero, M., et al. (2025) · Heart Rhythm · doi:10.1016/j.hrthm.2025.07.058 · Cited by 3
The weight of choices: Prioritizing lifestyle over GLP-1 receptor agonist therapy in managing MASLD
Schattenberg, J. M., & George, J. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101401 · Cited by 3
Self-citationIncretin-based therapies for liver disease
Kotsiliti, E. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00961-w · Cited by 2
Challenges in the management of MetALD after liver transplantation
Cucco, M., Becchetti, C., Scaravaglio, M., Dispinzieri, G., Bolis, F., Bagalà, L., Strollo, M., Orlando, M., Perricone, G., Mazzarelli, C., et al. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.144 · Cited by 2
Lin, J., Green, V., Sohal, A., & Roytman, M. M. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002234 · Cited by 3
Cai, Y., Xie, S., Xu, L., Chen, J., & Cai, J. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178088 · Cited by 2
Attia, A. M., Zavareh, M. S. R., Yeo, Y. H., Kwak, M., Kim, H., Noureddin, M., & Yang, J. D. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000806 · Cited by 2
“[29,30] There are other drugs under evaluation in clinical trials for the treatment of MASH with fibrosis, such as survodutide [31] and tirzepatide.”
Self-citationXiao, Y., Yu, S. P., Zhang, Y., Chen, J., Yan-qun, L., Liu, X., Sun, C., & Deng, C. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70105 · Cited by 3
“32 Notably, one publication 32 presented results from two RCTs (NCT03175211 and NCT03591718), while the remaining publications 23,24,30,31 each described a single trial.”
InfluentialSurvodutide: A Dual GLP-1/Glucagon Agonist Reshaping Cardiometabolic Care
Arun, A. J., Darji, B., Baig, M., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001062 · Cited by 2
Vilarrasa, N., & Pellitero, S. (2025) · Medicina Clínica · doi:10.1016/j.medcli.2025.107184 · Cited by 2
Pugliese, N., Spertino, M., Mercurio, M., Ciardullo, S., Perseghin, G., Hassan, C., Vettor, R., Petta, S., & Aghemo, A. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.10.018 · Cited by 2
The dual GLP-1–glucagon agonist pemvidutide in MASH: a phase 2b trial
Tacke, F. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02304-9 · Cited by 3
Metadata
- Authors
- Sanyal, A. J., Bedossa, P., Fraessdorf, M., Neff, G. W., Lawitz, E., Bugianesi, E., Anstee, Q. M., Hussain, S. A., Newsome, P. N., Ratziu, V., Hosseini-Tabatabaei, A., Schattenberg, J. M., Noureddin, M., Alkhouri, N., & Younes, R.
- Affiliations
- Inserm (FR)
- From the Stravitz–Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University School of Medicine, Richmond (A.J.S.); Liverpat and University of Paris (P.B.), and Sorbonne Université, Institute for Cardiometabolism and Nutrition, Assistance Publique–Hôpitaux de Paris, INSERM Unité Mixte de Recherche Scientifique 1138, Centre de Recherche des Cordeliers (V.R.) — all in Paris; Boehringer Ingelheim, Ingelheim am Rhein (M.F., S.A.H and R.Y.), Saarland University Medical Center, Homburg (J.M.S.), and University of the Saarland, Saarbrücken (J.M.S.) — all in Germany; Covenant Metabolic Specialists, Sarasota, FL (G.W.N.); Houston Methodist Hospital and Houston Research Institute, Houston (M.N.), and the Texas Liver Institute, University of Texas Health San Antonio, San Antonio (E.L. and N.A.) — all in Texas; the University of Turin, Turin, Italy (E.B.); the Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, and Newcastle National Institut...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-07-25
- Volume
- 391
- Issue
- 4
- Pages
- 311-319
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4399439504
- Cited by
- 528
- References
- 28
- Citations by year
- 2026: 212 · 2025: 237 · 2024: 79
- FWCI
- 159.28
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, cc-by-nc-nd)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- survodutide, nonalcoholic steatohepatitis, liver fibrosis, glucagon receptor agonist, GLP-1 receptor agonists, liver fat, histologic improvement, dose-response relationship, adverse events, non-alcoholic fatty liver disease, drug safety and efficacy, dose escalation, maintenance phase
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Fatty Liver, Female, Humans, Injections, Subcutaneous, Liver, Liver Cirrhosis, Male, Middle Aged, Receptors, Glucagon
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.